Valuation: PharmaEssentia Corporation

Market Cap 511B 15.83B 13.69B 12.79B 11.73B 22.06B 1,506B 22.41B 150B 58.88B 755B 59.44B 58.14B 2,496B P/E 2026 *
47.6x
P/E 2027 * 34.6x
Enterprise Value 485B 15.01B 12.98B 12.12B 11.12B 20.92B 1,428B 21.25B 142B 55.82B 716B 56.36B 55.12B 2,367B EV / Sales 2026 *
19.3x
EV / Sales 2027 * 13.8x
Free-Float
75.62%
Yield 2026 *
0.08%
Yield 2027 * 0.12%
1 week+11.00%
Current month+11.00%
1 month+11.00%
3 months+11.00%
6 months+11.00%
Current year 13.96
Extreme 13.963963
15.5
1 year 13.96
Extreme 13.963963
15.5
3 years 13.96
Extreme 13.963963
15.5
5 years 13.96
Extreme 13.963963
15.5
10 years 13.96
Extreme 13.963963
15.5
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Director of Finance/CFO - 2015-10-13
President - 2015-06-24
Director TitleAgeSince
Director/Board Member - 2000-05-08
Chairman - 2012-09-23
Director/Board Member - 2015-05-28
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+11.00% - - 16.47B
+8.49%+20.55%+69.74%+109.30% 62.92B
+1.25%+2.44%+32.55%+72.63% 54.32B
-1.09%+32.96%+19.95%+499.45% 28.73B
+2.72%+3.41%-15.88%-4.90% 22.91B
+10.83%+18.38%+52.76%+4.58% 21.65B
+6.50%+7.56%+38.20%-21.33% 17.76B
-3.88%+16.98%+199.30%+354.30% 16.47B
+6.20%+11.51%+34.94%+681.88% 15.48B
+3.58%+1.96%+44.61%+167.01% 13.12B
Average +3.46%+9.40%+52.91%+206.99% 28.15B
Weighted average by Cap. +3.94%+11.45%+49.71%+171.15%

Financials

2026 *2027 *
Net sales 25.07B 776M 671M 627M 575M 1.08B 73.88B 1.1B 7.36B 2.89B 37.03B 2.91B 2.85B 122B 34.57B 1.07B 926M 865M 793M 1.49B 102B 1.52B 10.14B 3.98B 51.06B 4.02B 3.93B 169B
Net income 10.85B 336M 291M 272M 249M 468M 31.99B 476M 3.19B 1.25B 16.03B 1.26B 1.23B 53B 14.97B 464M 401M 374M 344M 646M 44.12B 656M 4.39B 1.72B 22.11B 1.74B 1.7B 73.11B
Net Debt -26.52B -821M -710M -663M -609M -1.14B -78.17B -1.16B -7.78B -3.06B -39.18B -3.08B -3.02B -130B -34.73B -1.08B -930M -869M -797M -1.5B -102B -1.52B -10.19B -4B -51.3B -4.04B -3.95B -170B
Logo PharmaEssentia Corporation
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Company’s products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
Employees
131
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1,240.00TWD
Average target price
1,073.31TWD
Spread / Average Target
-13.44%

Quarterly revenue - Rate of surprise